{"id":"co-1-01","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"PARP inhibitors prevent the repair of single-strand DNA breaks by inhibiting the PARP enzyme. This causes accumulation of DNA damage in cancer cells, particularly those with BRCA mutations or homologous recombination deficiency, triggering apoptosis. CO-1.01 was developed as a PARP inhibitor for oncology applications.","oneSentence":"CO-1.01 is a poly(ADP-ribose) polymerase (PARP) inhibitor that blocks DNA repair mechanisms in cancer cells, leading to cell death.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:31:33.402Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer (BRCA-mutated or homologous recombination deficient)"}]},"trialDetails":[{"nctId":"NCT01233375","phase":"PHASE2","title":"Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Clovis Oncology, Inc.","startDate":"2011-04","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":19},{"nctId":"NCT01392976","phase":"PHASE1","title":"Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Clovis Oncology, Inc.","startDate":"2011-04","conditions":"Advanced Solid Tumor","enrollment":17},{"nctId":"NCT01124786","phase":"PHASE2","title":"A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)","status":"COMPLETED","sponsor":"Clovis Oncology, Inc.","startDate":"2010-05","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":367},{"nctId":"NCT01641575","phase":"PHASE1","title":"A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin","status":"TERMINATED","sponsor":"Clovis Oncology, Inc.","startDate":"2012-07","conditions":"Solid Tumor, Non-small-cell Lung Cancer, Lung Cancer","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CO-1.01","genericName":"CO-1.01","companyName":"Clovis Oncology, Inc.","companyId":"clovis-oncology-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CO-1.01 is a poly(ADP-ribose) polymerase (PARP) inhibitor that blocks DNA repair mechanisms in cancer cells, leading to cell death. Used for Ovarian cancer (BRCA-mutated or homologous recombination deficient).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}